The LLC Tumor Model for Lung Cancer

Screen your groundbreaking chemotherapeutics using the trusted Lewis lung carcinoma mouse model.

Lung cancer is a significant public health concern. This common and serious cancer has the highest mortality rates of all cancer types. Chemotherapy continues to be a crucial component of lung cancer treatment, but there is still a considerable need for more efficient therapies.

You can evaluate your novel cancer therapeutics with Melior’s reliable Lewis lung carcinoma mouse (LLC) model and benefit from the enhanced reproducibility of this popular lung cancer model.

The Current LLC Treatment Landscape

The multifaceted landscape for treating lung cancer continues to evolve. Chemotherapy remains a core component of the comprehensive management of lung cancer, with more than 60% of cancer patients over the age of 20 receiving chemotherapy as part of their treatment plan.

While chemotherapy remains an essential part of lung cancer treatment, there remains a significant need for more effective medicines, particularly for improving outcomes for patients with late-progression and treatment-resistant lung cancers.

Melior’s lung cancer models are an important tool to achieve this.

Evaluate Your Chemotherapeutic With The LLC Tumor Model

Scientists have used the LLC tumor model extensively since 1982 to study the effect of chemotherapy drugs, radiation therapy, and other lung cancer treatments. Numerous investigative studies rely on this model. These include inquiries that explore the role of specific genetic mutations in lung cancer and look at the complex biology and behavior of the disease.

The syngeneic model utilizes tumor cells from the lung of a C57BL/6 mouse and is widely used owing to its consistent tumor growth rates. The LLC tumor model is highly representative of the most common human adenocarcinoma subtype and has facilitated significant advancements in the search for novel lung cancer treatments.

This lung cancer model is complementary to our A549 lung xenograft model, making it the perfect first-pass screening tool for your chemotherapy R&D. The LLC tumor model’s intact immune system can be utilized for the study of novel classes of immune-oncology therapies. When paired with our high-efficiency oncology platform, Immuno-theraTRACE , your comprehensive study of immune-modulating agents extends to checkpoint inhibitors such as anti-PD-1.

Work With Consistency Using The LLC Tumor Model

Our well-established lung cancer model is an early screening tool for your novel chemotherapeutic that ensures you progress with the best candidates.

Experience an LLC tumor model that is:

  • Fast growing
  • Extensively used in the field
  • Consistent tumor growth rates for chemotherapeutic development
  • Compatible with Melior’s xenograft lung cancer model
  • Highly representative of the human adenocarcinoma subtype

Tailor-made Services: Designed with You in Mind

The LLC tumor model, like all of our syngeneic mouse models, includes efficient processes and expert guidance.
Our bespoke analyses include:

  • Tissue collection for immune cell analysis and profiling
  • Whole blood, spleen, and lymph node analysis
  • General observations, including pain analysis
  • Histology and IHC
  • Luciferase assay
  • IVIS imaging
  • FACS analysis
  • PK studies

Our custom support services include:

  • Face-to-face zoom calls
  • Ad-hoc consultation
  • Customized study proposals
  • Direct line to experienced project managers
  • Hands-on revision support

Don’t see what you’re looking for? Contact us for a comprehensive list of services.

Expand Your Applications with Immuno-theraTRACE

If you are looking for a fast and efficient way to screen immune-modulating agents, including immune checkpoint inhibitors, our oncology platform, Immuno-theraTRACE, allows you to test your immunotherapeutic across 8 syngeneic models.

Pair this platform with our LLC tumor model for a complete toolbox that evaluates and advances your cancer therapy in weeks.

Data Highlights: LLC Tumor Model Chemotherapy Validation

Subcutaneous Lung Cancer Model with Cisplatin and Paclitaxel

Chemotherapy Validation of the Lewis Lung Carcinoma Model.
This lung cancer model was created by injecting 2 x106 LLC cells into the rear flank of C57Bl/6 mice. Once mean tumor size reached 100~150mm3, the mice were randomized into 3 groups (Day 12): vehicle (IP normal saline), paclitaxel (30 mg/kg, IP twice per week), or cisplatin (4 mg/kg, IP twice per week). Tumor volume was monitored twice per week using calipers (A). At the end of the study (Day 23), animals were sacrificed, and tumors were excised and weighed (B, C). Both cisplatin and paclitaxel significantly inhibited tumor growth. Data are mean ± SEM; n=8 for the vehicle, n=5 for both paclitaxel and cisplatin; ** P<0.01, *** P<0.001 by Student’s t-test.

A Spotlight on Targeted Cancer Therapy

The LLC tumor model has uncovered new drug targets on the nanoscale. For instance, P-selectin is a molecule expressed on cancer cells that has an important role in cancer metastasis. This makes it a potential target for treating late-stage cancers.

Targeted drug delivery systems localize chemotherapeutics to specific target sites where they will have the best efficacy. In the near future, they may play a key role in improving chemotherapy and other cancer treatments.

The LLC tumor model continues to pioneer new strategies that target disparate drug classes on almost any tumor. Work like this is a bold step toward a world where even the most persistent lung cancers are treatable.

Are You Ready to Advance Your LLC R&D?


1. World Health Organization (2023) Lung Cancer. Available at: (Published 26 June 2023, Accessed: 15 August 2023).

2. National Cancer Institute (2023) Lung Cancer Treatment.Available at: (Published August 2023, Accessed: 17 August 2023).

3. Shamay, Y., Elkabets, M., Li, H., Shah, J., Brook, S., Wang, F., Adler, K., Baut, E., Scaltriti, M., Jena, P.V. and Gardner, E.E., 2016. P-selectin is a nanotherapeutic delivery target in the tumor microenvironment. Science translational medicine, 8(345), pp.345ra87-345ra87.